Safe Harbor Statement: Statements in this press not purely historical not purely historical online pharmacy.

Safe Harbor Statement: Statements in this press not purely historical not purely historical, including statements regarding Peregrine Pharmaceuticals intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note concerned, but results to differ materially from those that differ in such forward -looking statements. Among the factors that could differ may cause actual include, but are include, but are not limited to, uncertainties associated with completion of the preclinical and clinical trials for our technologies Third, the early phase of product development, the substantial costs of our products, like all to currently in development currently in development, preclinical studies or clinical trials, and obtaining additional financing to support our operations and the development of our products, to gain anticipated timing of regulatory filings and the potential success, obtaining regulatory approval for our technologies approval and compliance with government regulations in our business online pharmacy . Our business could be a number of other factors, including the risk factors listed from time to time in its SEC filings, including the company concerned, but not limited to, the Annual Report on Form 10 – K for the year ended 30 April 2008 and the Quarterly Report on Form 10-Q for the quarter ended 31 January 2009. The company cautions investors not too heavily on the too heavily on the forward-looking statements in this news release. Peregrine Pharmaceuticals assumes no obligation and disclaims any obligation to update or revise forward-looking statements in this press release.

The continuous in-line manufacturing process has European patent protection in the European Patent No. 1 638 989th time, the inventors at Peregrine and the Paul Scherrer Institute in Switzerland, which its rights the rights in the technology developed Peregrine Pharmaceuticals. Journal of Nuclear Medicine 50 :1178 – 1186th.

Other authors: Christoph C. Adewunmi Onafuwa – Nuga, McNamara, James Riddell IV , and Dale Bixby, all the ORDER, and Michael R. University of Texas at Health Sciences Center, in San Antonio, previously UM Heath System. Reference: 10.

Other Posts From "stomatology":

Related Posts